International Myositis Society - Newsletter 3/22

Logo-CER (1)

Upcoming papers on Myositis in press at our home journal "Clinical and Experimental Rheumatology - CER"

  1. The effect of COVID-19 pandemic on idiopathic inflammatory myositis patients: a single centre experiences
    T. Béldi, A. Vincze, B. Miltényi-Szabo, Z. Varga, K. Szabo, Z. Griger, M. Nagy-Vincze
  2. Interstitial lung disease in adult patients with anti-NXP2 antibody positivity: a mulicentre 18-month follow-up
    T. Yan, Y. Du, W. Sun, X. Chen, Q. Wu, Q. Ye, S. Chen, J. Xue
  3. Use of JAK inhibitors in dermatomyositis: a systematic literature review
    J.J. Paik, G. Lubin, A. Gromatzky, P.N. Mudd, M.P. Ponda, L. Christopher-Stine
  4. Different clinical phenotypes in anti-melanoma differentiation-associated protein 5-associated positive dermatomyositis
    P.A. Olivo Pallo, S.K. Shinjo
These myositis-related articles will appear at CER, and can be found there in the press section.

Summary report from the GCOM 2022

After two postponements and with a delay of more than a year, the 4th Global Conference on Myositis - GCOM could finally start on June 6, 2022. This World Myositis Congress, which was held in hybrid form for the first time, was attended by 470 participants from 33 countries - 260 of whom were local. Here is a brief summary report from GCOM in Prague 2022 (from the patient's perspective).
GCOM_2022 (2)

European Neuromuscular Centre - ENMC

From October 8-10, 2021, the 256. ENMC International Workshop on "Myositis specific and associated autoantibodies (MSA-ab)" was held. A short public summary can be found here
Email Marketing Powered by MailPoet